Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and ...
Nkarta: Betting On The Turnaround
Nkarta's NKX019 offers hope for autoimmune treatment. Upcoming trial data and strategic moves could fuel recovery. Read more ...
Nkarta: Grinding Lower, Trying To Find Support
Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read ...
STAT10h
Down to their heart cells, women and men have cardiovascular differences that matter
Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...
PharmiWeb3h
IMFINZI® (durvalumab) approved in the US as first…
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
healthdigest.com on MSN1h
Warning Signs From Your Skin You Shouldn't Ignore
Often skin changes are harmless and clear up on their own, but others can be warning signs of something more serious ...
Le Lézard7h
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...